EUVIMEDEUVIMED entdecken
Metaanalyse

Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials

Xiaohua Hou, Jiangbin Wang, Qin Du, Dean Tian, Naizhong Hu, Deliang Liu, Fang Zhou, Li Xie, Liqun Gu, Kentarou Kudou, Shutian Zhang

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b24-00011 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Xiaohua Hou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori, Lansoprazole. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Helicobacter pylori eradication is crucial in the treatment of peptic ulcers caused by H. pylori infection, a disease highly prevalent in Asia. We present a pooled analysis of two randomized, double-blind, double-dummy, phase 3 studies evaluating the efficacy and safety of vonoprazan-based bismuth-containing quadruple therapy for H. pylori eradication. Patients aged ≥18 years with endoscopically confirmed duodenal or gastric ulcers were randomized 1 : 1 to receive vonoprazan 20 mg or lansoprazole 30 mg once daily for up to 6 (duodenal ulcers) or 8 weeks (gastric ulcers). H. pylori-positive patients received vonoprazan- or lansoprazole-based bismuth-containing quadruple therapy for the first 2 weeks. H. pylori eradication was determined using the carbon-13 urea breath test at a follow-up visit 4 weeks post-treatment. The H. pylori eradication rate was 90.6% with vonoprazan vs. 85.2% with lansoprazole (difference: 5.4%; 95% confidence interval (CI): -0.1, 10.8). H. pylori eradication rates were 7.1% (95% CI: 1.4, 12.8) and 12.6% (95% CI: 3.9, 22.0) higher in patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriLansoprazolePeptic UlcerProton Pump InhibitorsSulfonamidesAdultAgedFemaleHumansMaleMiddle AgedAnti-Ulcer AgentsBreath TestsDouble-Blind MethodDrug Therapy, CombinationPyrrolesTreatment OutcomeClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Helicobacter pyloribismuth-containing quadruple therapylansoprazolepeptic ulcervonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAnti-Bacterial AgentsAnti-Ulcer AgentsLansoprazoleProton Pump InhibitorsPyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
  • Department of Gastroenterology, China-Japan Union Hospital, Jilin University.
  • Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine.
  • Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
  • Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University.
  • Department of Gastroenterology, The Second Xiangya Hospital of Central South University.

Zitieren

APA

Hou, X., Wang, J., Du, Q., Tian, D., Hu, N., Liu, D., Zhou, F., Xie, L., Gu, L., Kudou, K., & Zhang, S. (2024). Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00011

Vancouver

Hou X, Wang J, Du Q, Tian D, Hu N, Liu D, et al. Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00011

BibTeX
@article{Hou2024,
  author = {Hou, Xiaohua and Wang, Jiangbin and Du, Qin and Tian, Dean and Hu, Naizhong and Liu, Deliang and Zhou, Fang and Xie, Li and Gu, Liqun and Kudou, Kentarou and Zhang, Shutian},
  title = {Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b24-00011}
}
Kostenlos starten →